Other innovations
If your innovation doesn’t fit any of the active categories then this is the place to submit your innovation for feedback and the opportunity for wider adoption across the region.

Ideas (Wellness and prevention of illness)

Innovation 'Elevator Pitch':
Children are at risk of serious harm or even death because adults are mixing alcohol consumption with caring and parental responsibilitie. This campaign poses the question - "when parents drink, who's in charge?'
Overview of Innovation:
Parents from all backgrounds are putting their children at risk when they drink alcohol at home.

The 'Who's In Charge?' campaign from Birmingham Community Healthcare NHS Trust depicts real life child harm scenarios and asks – ‘when you drink, who’s in charge?’

The campaign was conceived in response to concerns that growing numbers of babies and children are at risk of serious harm because of the way their parents consume alcohol at home.

Safeguarding professionals warn that children are being placed in danger and even losing their lives because adults who in many cases do not consider themselves excessive drinkers are not exercising normal levels of care and attention while drinking or recovering from the after-effects of over-indulgence in alcohol.

And they warn of a ‘double jeopardy’ effect - that drinking too much alcohol can not only reduce a parent’s capacity to appropriately respond to children’s needs, but also make the drunken adult an active danger to the child.

One of the most worrying trends identified locally and nationally is a rise in the number of baby deaths connected with sleeping on a sofa with an adult who is under the influence of alcohol, the number of children left to care for their younger siblings and the impact of the example of parents’ drinking patterns on young people.

The number of victims of Sudden Infant Death Syndrome who were sleeping with a parent on a sofa has risen.

The campaign urges parents, and others with responsibility for children, to be aware of a range of potentially dangerous consequences if no adult remains sufficiently sober and aware of children’s needs or whereabouts.


In one year in Birmingham alone: 
  • 82% of babies who died from Sudden Infant Death Syndrome were sleeping with a parent at the time
  • 56% of these deaths were on a sofa; 44% in the parental bed.
  • 78% of the fatalities were associated with parental alcohol use at the time
  • while 44% involved parental drug use.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Wellness and prevention of illness / Education, training and future workforce / Person centred care
Benefit to NHS:
  • supportive of statutory safeguarding responsibilities through reduced risk of harm to children and young people
  • supportive of adult clinical services due to reduced risk of harm to adults through excessive alcohol consumption.
  • community cohesion
  • marketing and education resources for professionals eg. health visitors, school nurses.
Initial Review Rating
3.60 (2 ratings)
Benefit to WM population:
  • reduced risk of harm to children and young
  • reduced risk of harm to adults through excessive alcohol consumption.
  • community cohesion
Current and planned activity: 
A set of photographs has been commissioned depicting hard-hitting photographic case study scenarios based on real life evidence from serious case reviews and other reported incidents.

AVAILABLE TO OTHER TRUSTS FREE OF CHARGE - If you wish to use these in your organisation, please contact David Disley-Jones or MidTECH Innovations (www.midtech.org.uk).

A simple logo was designed and has been trade-mark protected with the IPO.
A set of posters has been produced which have been displayed in a variety of locations.
A set of aide memoire cards has been produced for use by professionals such as health visitors and school nurses to generate discussion and raise awareness.
Who's In Charge? has been licensed to British Armed Forces in Germany for use on military bases, in acknowledgement of the issue of alcoholic consumption among military families.

 
What is the intellectual property status of your innovation?:
The logo and the use of the phrase 'Who's in Charge?' (in certain contexts) has been trade-marked with the IPO.
The photographs are copyright BCHC/Roy Peters Photography.
Return on Investment (£ Value): 
low
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Simple
Co-Authors:
Read more
Hide details
David Disley-Jones 30/05/2017 - 15:05 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
SEEING WHAT OTHERS SEE, AND WHAT THEY EXPERIENCE IN THE PROCESS
Eye Control, Eye Perception, Eye Emotion
Affordable,Intelligent Digital Eyewear
Overview of Innovation:
Eye Hyper Tracking System - Smart Wearable
Viewpointsystem has developed a completely new system to measure and understand human perception through the eyes.
The Eye Hyper Tracking doesn't just capture the line of sight,but also how the person reacts to what is seen. The system in the form of smart lightweight safety rated glasses allows extremely precise measuring of observations and insights coupled with the ability to SHARE what is being seen via REMOTE LIVE STREAMING.
  • Telemedicine - A health professional can conduct or instruct a procedure with the aid of a precise hands free view.
  • Training - Any aspect of training can be covered, be it a live event or with the ability to record 'what is seen' it can be then shared, learned from and shown as a unique prespective into the instructor or wearers' viewpoint and preception
  • Paramedic / 1st Responder - Imagine a world where an expert can see what you are looking at and give you on the spot support. Envisage a paramedic or 1st responder calling in advance to show the recieving hospital the extent or seriousness of a situation
  • Improving Results - Instructions are often given and confirmed as being understood, communication is key in getting things right first time. With a view of 'how' to carry out a instruction, in certain circumstances a person viewing your first attempt is both supportive and safe.
  • Reducing Costs - Specialists cannot be everywhere all of the time. With a live streaming function, they are only ever a click away to see what you see, thus reducing the need to travel, rebook appointments, move from place to place.
The system has truely endless possibilites. Having been in the scientific arena for a number of years it is proven to be relaible and very accurate. Our system takes the technology from the lab into the real world, being light, highly mobile and robust it is user friendly, simple and smart.

The revolution in the measurement and interpretation of human perception has truly begun.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
NHS Benefits
  • Efficiency - Simulation of scenarios for training
  • Efficiency - Centrally situated teams all viewing the same situation though the same perspective
  • Efficiency - 1st Responder / Paramedic support given, time saved when arrival at hospital, faster turnaround times
  • Efficiency - Right 1st time approach to training, supportive and inclusive
  • Efficiency - Faster turnaround times for paramedics at hospitals
  • Cost Benefit - Travel of key staff and personnel
  • Cost Benefit - Training budgets reduced to all areas
  • Cost Benefit - Specialists can support remotely, no need to always attend sites
  • Cost Benefit - Abilty to simulate a scenario or situation. Feedback could be given by instructor remotely
  • Cost Benefit - General hospital infastructure - The system is applicable to services outside of medical arena - IT support, Machinery supplier support, building support.
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
The system is designed to support all industries with medical being a specific area.
Our system not only enables faster, safer, most cost efficent ways of doing things, it provides an enabler to reduce time and improve effectivness.
Any improvements or cost savings can only help improve patient or colleagues healthcare, reduce waiting lists and improve services. It is also key to ensure the highly trained dedicated staff have every possible piece of equipment to help improve their working life balance and conditions.
Current and planned activity: 
Our current status is to engage with all 15 AHSN's in the UK.
Our system was only launched in UK in Sept 2016, and we have only just started to engage with the UK health sector.
We have a number of doctors, paramedics and hospitals trialing our system in Europe, and we have just engaged with a leading surgeon in USA who is keen to try our technology, as he was the first surgeon to use Google Glasses to carry out a live stream procedure.

Our primary intention is to be seen and heard by the NHS. We are keen to visit and demonstrate the system and possibilites first hand, as we are not a concept as we have an actual fully functioning system ready to use.
What is the intellectual property status of your innovation?:
We have IP on certain elements of the system.
Eye tracking is commonly adopted in VR/AR system is various guises.
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Read more
Hide details
Graham German 23/02/2017 - 11:14 Publish Login or Register to post comments
5
1
Votes
-99999
Innovation 'Elevator Pitch':
Nearly 40% of NHS staff have reported feeling unwell as a result of stress (NHS Staff Survey).
Mental Health First Aid is an evidence based programme designed to help individuals to prevent, identify and tackle stress and mental health problems.
Overview of Innovation:
NHS staff are more likely than the rest of the working population to become patients, increasing demands on the system they work in (King's Fund).

Altruist Enterprises are experienced in providing training to help organisations to prevent, identify and tackle stress within organisations.

Since forming in 2013, we have grown from 1 trainer to 3 members of staff and 10 contracted trainers delivering courses nationally with notable customers including Birmingham Children's Hospital, Solihull Council and WMAHSN.

We currently offer the following main courses to the NHS:

Resilience Training - A 3 hour course which helps employees to manage stress and build resilience in an everchanging work environment using proactive approaches.

“I learnt how to recognise situations in my daily working and home life that I can work on to reduce my personal stress and build my resilience. We were taken through a process which allowed us to challenge our negative thoughts and look at things from a different perspective. A very helpful course”. Federica Merella, Consultant Anaesthetist, Birmingham Children’s Hospital

Mental Health First Aid Lite - A 3 hour evidence based mental health awareness course accredited by the Royal Society for Public Health.

“We learnt about some of the main mental health problems, how to support others who may be experiencing issues and also discussed ways to support our own well-being. The course was very thought provoking”. Sophia Nasreisfahany, Solihull Council

Adult Mental Health First Aid - A 2 day evidence based indepth mental health awareness course accredited by the Royal Society for Public Health.

"This 2 day training delivered by Altruist was one of the most fulfilling training courses I have attended.  Having worked in the NHS for 17 years and managing staff for 13 of those I found this course enlightening.  It compounded how mental health affects us all no matter what your background is.  It also really tackled the stigma of using the words “mental health”.  Practical advice, tips and scenarios were used to give us a toolbox of strategies to help staff.  On reflection of my own career I now realise I have been in this position many times and now I feel more empowered and equipped to deal with these sensitive situations". Helen Hunt, WMAHSN

We measure outcomes including increases in knowledge and personal confidence in supporting others. We can also measure reduction in absenteeism and recently helped a local charity reduce absence by 25%.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Wellness and prevention of illness / Education, training and future workforce
Benefit to NHS:
Increase in Confidence and Knowledge - Consultant Anaesthetists at Birmingham Children's Hospital saw a 32% increase in personal confidence of managing stress levels following our Resilience course. (Delegates are asked to rate their personal confidence, scale of 1-10 in managing stress levels and knowledge of resiliency building skills before and after the course).
Reduction in sickness absence - Stress affects the health and quality of life of staff. The benefits of tackling work-related stress are the obvious ones of more staff at work more of the time, and the reduction in sickness absence and its associated costs.
Improved Employee and Community Engagement - It also demonstrates the organisation’s commitment to its workforce and to addressing their health needs. This, in turn, affects how the organisation is perceived by both staff and the local community in terms of being a good employer.
Reduction in costs-  employees who are away from work because of stress will have to have their work covered by other staff, frequently bank or agency. Investment in stress management can reduce the need for this expenditure – one NHS trust reported a saving of £500,000 a year in agency cover costs.
Improved patient care - Chronic stress can lead to an increase in accidents and cause safety issues for staff and patients. Investment in resilience and stress management training will help reduce the risk.
NHS seen as innovators - There is a current campaign in government to make Mental Health First Aid a compulsory element of First Aid training in the workplace.
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
Mental Health costs the West Midlands region £12 billion a year & affects around 70,000 people (West Midlands Combined Authority). Poor mental health results in enormous distress for individuals, greater pressure on public services and reduced economic productivity.
Current and planned activity: 
We recently delivered our Resilience course to doctors at Birmingham Children’s Hospital. We also recently delivered a Mental Health First Aid pilot course to NHS staff in partnership with WMAHSN.
 
We appreciate that the NHS are a large employer and that budgets are continuously being squeezed as demand for services increases. That is why we would introduce a Train the Trainer programme which will allow knowledge, skills and best practice to be cascaded throughout the organisation.
 
Trainers will be selected based on their knowledge of mental health, facilitation skills and willingness to be the go-to person for any concerns.
 
We envisage that the Train the Trainer programme will include an initial mental health workshop to give delegates the opportunity to experience the course first hand, presentation skills and facilitated tasks and assessments.
 
Alongside this, Altruist’s expert trainers will also continue to deliver Resilience and Mental Health First Aid courses to selected groups.
What is the intellectual property status of your innovation?:
Altruist Enterprises are licensed providers of the Mental Health First Aid courses.
The Resilience course and its materials were produced and is owned by Altruist Enterprises UK Limited.
​Altruist Enterprises UK Ltd was incorporated in February 2013 and began trading in August 2013. 
www.altruistuk.com and altruist.community and its content is owned by Altruist Enterprises UK Ltd.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
2
Regional Scalability:
We would introduce a Train the Trainer programme which will allow knowledge, skills and best practice to be cascaded throughout the organisation therefore aiding scalability.
Alongside this, Altruist’s expert trainers will also continue to deliver Resilience and Mental Health First Aid courses to selected groups. Altruist operate nationally and work with 10 regular contracted trainers and have access to a further bank of 35 specialist trainers.

We are currently 1 year into a 2 year training contract with Stoke on Trent City Council, delivering the Mental Health First Aid Lite course to employees. Delegates that have attended these courses have seen between a 30% - 60% increase in personal confidence of supporting others experiencing stress/mental health problems.
Measures:
All delegates that attend our training courses are required to complete an evaluation form to measure the impact that the workshop has had. Delegates are asked to rate their knowledge of resiliency building skills, personal confidence in managing stress and confidence in supporting others on a scale of 1-10 before and after the course. Percentage increases are then calculated. For this particular contract, we would look for between a 35% - 55% increase in knowledge/confidence following courses.

We will aim for a minimum of 80% good/very good feedback from delegates.
Adoption target:
Minimum of 3 x NHS Trusts enagaged
3 x 5 day train the trainer programmes to be delivered within first 12 months
24 x 3 hour courses to be delivered within the first 12 months
12 x 2 day courses to be delivered within the first 12 months
Read more
Hide details
Katie Buckingham 03/02/2017 - 14:42 Detailed Submission 1 comment
6
2
Votes
-99999
Innovation 'Elevator Pitch':
Stratification of patients into Risk Groups greatly enhances management of long-term conditions, COPD, Diabetes, Heart Failure, etc also supporting early discharge preventing readmissions.
Overview of Innovation:
Stratification of patients into Risk Groups, even for the same condition, greatly enhances the focus, scalability and agility in response to changing demand. Used to manage people with long term conditions such as COPD, Diabetes, Heart Failure, etc…… as well as supporting early discharge to prevent readmissions.
  1. Population-level Low-Risk Patients (75%): Free for BYO devices (smart or text message) for self-management and education. No remote monitoring but data can be shared with GP systems for access by all clinical stakeholders. Minimum cost to the NHS. Scalability is limitless. Activ8rlives4 Wellness and Food Diary App is available FOC via the App store and Google Play.
  2. Rising Risk Patients (20%): Where there is no smart phone availability or poor IT skills: CliniTouch Vie as below. Where Patients own Smartphone/Tablet and have WiFi: Activ8rlives Lung Health, Diabetes Health and others. Medical monitors could be prescribed on loan initially on early discharge (as one use case) and then transitioned to BYO Smartphones and monitors. Alternatively, they may be stepped-up by prescribing further monitors and data reviewed remotely at greater frequency.
High Risk Patients (5%): CliniTouch Vie: locked-down tablet provided with integrated 3G for connectivity, intensive monitoring, education and empowerment with integrated direct messaging and video support. Dynamic care plans and intelligent algorithms enable automatic triage for healthcare team. Fast, simple and quick to implement for the most at-risk and vulnerable of patients.

For further information contact
Kevin A. Auton, PhD, Managing Director, Aseptika Limited kevin.auton@aseptika.com www.activ8rlvies.com
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Spirit Healthcare: Leicester City CCG, combining telemonitoring, specialist nurse interventions and health coaching in COPD, demonstrated reduced admissions by 67% and also improved patient’s experience of care. http://www.magonlinelibrary.com/doi/10.12968/bjhc.2016.22.3.123
  1. 67% reduction in unscheduled admissions amongst patient cohort - multiple regression analysis revealed that CliniTouch telemonitoring (Spirit Healthcare) was the only intervention that statistically significantly (P<0.05) reduced unscheduled admissions.
  2. Overall reduction of 9.1% in all COPD admissions - despite the harsh winter of 2013/14, there was an overall reduction in all COPD admissions, easing winter pressure and bed blocking.
  3. Effective in managing re-admissions – number of admissions per head reduced from 3.13 to 1.02 per year (p<0.001). Nurse interventions required to manage patients also reduced, improving caseload management. The benefits were realised across the whole health economy. 
  4. Improved patients’ experience of care – patient feedback demonstrated higher levels of confidence, knowledge about their condition and positive behavioural change. 
Activ8rlives Lung Health (Sensor 3) telehealth reduced unplanned admissions and improves self-management. Undertaken clinical trials supporting Self-Care in Cystic Fibrosis (Papworth Hospital), COPD and Bronchiectasis (Portsmouth NHS) and on-going in Liverpool Heart and Chest Hospital for 45 COPD patients (Dr Dennis Wat and Mark Jackson, funded by NWC AHSN). Aseptika is an innovation partner for the Sheffield NHS Test Bed.
Liverpool Heart & Chest Hospital, Knowsley Respiratory Community Team. Sensor 3 self-care project allows patients with COPD to monitor and track their vital signs at home, using a secure and easy to use Lung Health 3 App, developed by Aseptika Ltd. The whole process takes approximately 12 minutes each day. The patients are provided with the equipment to allow daily measurements of blood pressure, heart rate, oxygen saturation, body weight, temperature, peak flow, FEV1 and physical activity levels. The measured data is displayed as simple charts. 
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
Patients are educated and supported to interpret the data to enable improved understanding of their health status.
  1. Prevent unnecessary admissions as patients have access to 24/7 the COPD rapid response team as soon as there is any health deterioration for treatment to prevent unnecessary admission into hospital. The collected data is currently being analysed by Knowsley Respiratory Community Team.
  2. Technology improves patient’s confidence in managing their COPD. For patients who experience frequent infections and disease exacerbation, this can be a lifeline. In Liverpool 90% of participants would recommend to Friends and Family. 60% would be prepared to make a financial contribution of £300 to support costs.
Current and planned activity: 
Spirit Healthcare group of companies can now provide one of the most comprehensive range of solutions to support patients of all ages, all IT abilities, all levels of disease severity and across a wide range of disease areas: respiratory, cardiovascular, diabetes and frail elderly.

Aseptika currently have in development: (a) on-ward and home-use sputum test for Pseudomonas aeruginosa (patent protected); (b) BuddyWOTCH – a 3G connected wearable medical device (SpO2, HR, Temperature, Respiration Rate with Sit-to-Stand and 5-minute walk test) – patent applied for; (c) a population screening test for Atrial Fibrillation using pulse oximeter technology (patent protected), and (d) Bluetooth inhaler usage monitor.  
What is the intellectual property status of your innovation?:
IP is retained by respective companies within the Spirit Healthcare group of companies.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
3
Read more
Hide details
Kevin A. Auton 12/01/2017 - 10:55 Publish Login or Register to post comments
5
1
Votes
-99999
Innovation 'Elevator Pitch':
Optimised Equivalent® to best performing & highest volume branded orthopaedic implants (>1,000,000 patients), coupled with significant savings. Equivalent manufacture, materials, tolerances & sizes, along with operational technique & instrumentation.
Overview of Innovation:
The UK is the first country in the world to benefit from applying the principle of generics to orthopaedic products. Generic medicines have been a core part of the NHS since the 1980s, offering the same clinical outcomes for patients as originator drugs and now contributing over £12 billion in savings every year that can be reinvested into the health service (1)

With >66,000 NHS hip replacement operations performed every year (2) switching to generic hip implants from the current market leaders, the NHS could save up to £120 million by 2020 - enough to fund over 1,400 junior nurses every year (2,3,4)

This is well-timed following Lord Carter’s Review, which found that large efficiency savings can be made by all NHS hospitals – notably in orthopaedics. Some of these savings can be made by reducing the current variation in patient outcomes (5)
 
Evidence from over 1,000,000 hip replacement operations in published registry data shows that some of the most widely used devices with the lowest possible revision rates can be provided at a significantly reduced cost due to patent expiration. Orthimo have produced Optimised Equivalent® implants to the branded versions, providing significant cost savings without compromising patient outcomes.

The manufacturing of the Optimised Equivalent® implants are by well established suppliers with many decades of experience in manufacturing orthopaedic implants for the large Orthopaedic companies, further strengthening the equivalence value proposition.  Both the surgical instruments and techniques are also equivalent.

As a further indicator of reassurance, the Department of Health recently purchased a significant quantity of Optimised Equivalent® implants through a forward buying fund, which can be obtained via NHS Supply Chain.
 
At a time of unprecedented cost pressures on Healthcare systems worldwide, Optimised Equivalent® implants make a valuable contribution towards maintaining high quality hip replacement services within the limited resources available.

This means patients receive the best clinical outcomes at significant cost savings for hospitals.

http://www.odep.org.uk/Product.aspx?pid=2301

http://www.beyondcompliance.org.uk/product.aspx?pid=2301

https://my.supplychain.nhs.uk/Catalogue/product/fjh10279

Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence
Benefit to NHS:
Orthimo provide equivalents of the best performing and most commonly used branded orthopaedic implants, as proven by registry data of over 1,000,000 patients. Similarly to generic pharmaceuticals, which the NHS already takes advantage of, Orthimo products come with significant savings of 30-60%. This could save the NHS up to £120million by 2020.
 
These can be provided with minimal disruption to services and procedures due to the sizes, instrumentation and operative technique being equivalent to the most commonly used branded products. They are available through a simple and transparent pricing structure, which can be via the Total Orthopaedic Solutions, Chester or NHS Supply Chain frameworks.
 
As an indicator of reassurance, the Department of Health recently purchased a significant quantity of Optimised Equivalent ® implants through a forward buying fund, which can be obtained via NHS Supply Chain. With most Trusts using one or more of the branded reference components, a transition to make savings has never been easier.
Initial Review Rating
2.60 (1 ratings)
Benefit to WM population:
Orthimo provides generic versions of the best performing hip implants, this means patients in the West Midland area can receive the best clinical outcomes at significant savings to the hospital and trusts in the region. 
 
In the West Midland approximately 6,000 hip replacements are performed per annum. If, at a conservative estimation, these cost £700 each on average, generic hip implants could save the West Midland area over £1.5m per annum.
Current and planned activity: 
With Optimised Equivalents being available via all Orthopaedic frameworks, Orthimo are seeking Surgeons to conduct small volume evaluations or for Trusts to allocate a proportion of their hip work.

As with the generic pharmaceutical industry, there is a need to establish a policy change to ensure the responsible and active use of generic orthopaedic implants.
  • Procurement: -  Require sales and marketing to Trauma & Orthopaedics departments and procurement
  • Evaluation - Seek ‘Beyond Compliance’ service evaluation centres for uncemented range
  • Adoption:- Seek Hospitals/Surgeons to conduct small volumes of procedures
  • New Product Development:- Require experts to propose and support development of new products
What is the intellectual property status of your innovation?:
All IP resides with Orthimo.

Orthimo holds BSI CE Mark for all implants.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:
Optimised Equivalents use the most common and best performing branded reference products. These are used in most Trusts across the country, and so an introduction will have minimal disruption. We use the same sub-contracted manufacturers and logistics which the large companies use, and so supply can be scaled rapidly. 
Measures:
Our products are being used via the Beyond Compliance process. This data will be used to apply for successive ODEP ratings when the criteria are acheived. 
Adoption target:
We are looking for Trusts to use Optimised Equivalents for their low risk, common primary elective total hip replacement procedures. It has been estimated that this would be in excess of 60% of cases. 
Read more
Hide details
Oliver Wylie 09/01/2017 - 15:16 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Self-care smartwatch reducing burden on health service and keeping people out of hospital
Overview of Innovation:
Aseptika Limited (Activ8rlives), developers of a range of self-monitoring medical devices, some in the form of wearable technologies, aimed at assisting patients to self-manage long-term health conditions at home, is already having impact in this field. The early identification via home self-monitoring of an impending change in condition may allow for earlier intervention by starting antibiotics (“rescue pack”) days earlier, thereby reducing the need for lengthy hospitalisation.
Aseptika and Renfrew Group International (RGi) have been working together on the development of the Activ8rlives BuddyWOTCH™.This solution will provide “expert” pathways for use by both patient/carers and the healthcare team to inform, manage and report the success of self-care plans so that patients can remain independent at home, with a better quality and more sustainable model of care. Such solutions must be truly wearable, comfortable, ergonomic, attractive, and suitable for use with minimal training by consumers, often age-related. Achieving this whilst developing the packaging design, mechanical engineering and design for production has been the Renfrew Group team’s priority.

The BuddyWOTCH project (Pictured), funded under the SBRI Healthcare programme, is for the development of a wearable health monitor Class 2 Medical Device. It comprises a wrist-worn smartwatch – “WOTCH” = Walking, Oxygenation, Temperature, Camera (image capture of medication, food and liquids) and Heartrate; a fingertip-worn sensing band for measuring blood oxygen – FingerBand SpO2; and a charging base – BaseStation.
Together, they form the BuddyWOTCH. Each element of the product system requires certifiable electronics and software, and RGi have created an innovative mechanical design tooling and moulding package.

This fully integrated medical sensing and recording system requires custom design in order to achieve medical device certification. Many other smartwatches are available but their short product lifetime and often inadequate design controls make it difficult for the manufacturers to achieve or maintain certification. The BuddyWOTCH development is challenging because of fundamental difficulty in accurately measuring dissolved oxygen levels when moving in daily life, the need for the devices to be miniaturised, have 99.5% wearability, stylish and comfortable for rest-of-life-wear, and the challenge of packaging a 24/7 Always Connected monitoring system into a smartwatch format.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Person centred care
Benefit to NHS:
The early identification via home self-monitoring of an impending change in condition may allow for earlier intervention by starting antibiotics (“rescue pack”) days earlier, thereby reducing the need for lengthy hospitalisation
Initial Review Rating
3.80 (1 ratings)
Benefit to WM population:
Assists patients to self-manage long-term health conditions at home
Current and planned activity: 
The BuddyWOTCH project, funded under the SBRI Healthcare programme, is for the development of a wearable health monitor Class 2 Medical Device. It comprises a wrist-worn smartwatch – “WOTCH” = Walking, Oxygenation, Temperature, Camera (image capture of medication, food and liquids) and Heartrate; a fingertip-worn sensing band for measuring blood oxygen – FingerBand SpO2; and a charging base – BaseStation.
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
michael phillips 03/01/2017 - 11:05 Publish Login or Register to post comments
4
1
Votes
-99999
Innovation 'Elevator Pitch':
65m urine specimens analysed annually in the UK breaks down to 250,000 every working day, of which 45,000 will be unreliable. This means 45,000 patients daily who will not be treated for urine-based infections. Peezy Midstream means they can.
Overview of Innovation:
Peezy Midstream can save the NHS £30m in reduced retesting of the most common diagnostic procedure.

It is a simple but innovative device that automatically captures clean-catch urine from men, women and children (from toddler age). It is especially valuable for the elderly and pregnant women for whom accurate urine screening is essential.

The average national mixed growth rate reaches from 0.38% to over 70%; the average is 18% - that's nearly 1 in 5 patients who will not receive accurate right-first-time treatment from their urine specimen.

Peezy Midstream reduces mixed growth rates to 1.5%, which means many more patients will be treated right-first-time, saving the NHS as a whole over £30m in direct retest costs and over £1bn indirectly through saving repeat staff and resource time.

Peezy Midstream captures urine specimens hygienically - it prevents spills and splashing, improving infection control in healthcare settings. It can be held by the tube if help needs to be given - the assistant does not risk becoming soiled either.

Dignity is implicit; easy Peezy is comfortable, quick and removes the need to start-stop-start when giving a midstream urine specimen.

There is no down-side to using Peezy Midstream. It saves lives, saves time and money and reduces unnecessary broad spectrum anitbiotic prescribing. Peezy is poised to make novel cancer urine tests more efficient too.

Each Peezy kit costs just 87p on the NHSSC; use ten for every retest. Available on the NHS Supply Chain and on the UK Drug Tariff - growing in popularity with midwives and care givers to the elderly.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Clinical trials and evidence / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Peezy Midstream delivers huge cost and efficiency savings plus clinical benefits:

(See attached WM mixed growth data and separate cost savings model)
  • Reduction of average West Midlands mixed growth rate of 17.5% to 1.5%
  • West Midlands direct savings of £307,798
  • West Midlands indirect savings of £12,339,337 (see attached WM cost savings model)
  • reduced urine specimen mixed growth from West Midlands average  to 1.5%
  • right-first-time urine analysis, diagnosis and treatment - don't see the same patient twice for the same problem
  • delivers specimen into 10ml tube that fits most automated laboratory urine analysers (no decanting in lab)
  • no soiling, dry tube, clean toilets: more hygienic for healthcare professionals
  • targeted prescribing, reducing need for broad spectrum antibiotics
  • improved infection control: no spills or splashing of urine
  • works equally for men, women and children (from toddler age)
  • excellent for pregnant women where antenatal screening must be super-accurate; they don't have to see the funnel is in place - they can feel it
  • antenatal screening accuracy for maternal diabetes, pre-eclampsia
  • excellent for the elderly prone to UTI, which can affect both wellbeing and behaviour
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
  • West Midland Patient Savings of £90 (please see attached WM cost savings model, Patient Savings tab)
  • Accurate urine specimens mean prompt, accurate diagnoses
  • Patients will no longer need to visit their GP more than once for urine-related illnesses
  • They will receive the correct, targeted antibiotic, helping the fight against anitmicrobial resistance, encouraged by over prescribing of broad spectrums
Current and planned activity: 
  • Peezy Midstream is on the NHS Supply Chain at 87p (Peezy, tube, genital wipe)
  • It is approved by NHS Prescription Services and on the Drug Tariff for prescribing
  • Quality Improvement Audit at Barts (London) shows reduction in mixed growth from 17.5% to 1.5%
  • Quantative clinical study results pending from Stanford Medical School
  • Peezy currently part of MS Rapid Diagnostics Pilot, London
  • Prescribing growing amongst antenatal population
  • In use within some NHS departments: urology, outpatients, pre-admission, antenatal, A&E, Ambulance Services
What is the intellectual property status of your innovation?:
Patent and trademark granted:
  • UK
  • USA
  • Europe
  • China
  • Australisa
  • Asia
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
Easy; Peezy is available through the NHS Supply Chain
Forte Medical is happy to attend your location and brief staff on usage and instructions if necessary
Measures:
Reduced mixed growth
Reduced retesting
Reduced repeat appointments
Cost and efficiency savings
Adoption target:
6 months
Read more
Hide details
Giovanna Forte 09/11/2016 - 13:50 Detailed Submission Login or Register to post comments
5
1
Votes
-99999
Innovation 'Elevator Pitch':
Incredible amounts of expensive drugs are thrown away by pharmaceuticals companies, health trusts & GP surgeries due to refrigeration problems. Everyware technology enables remote data monitoring & intervention for pharmaceutical & food storage
Overview of Innovation:
The problem. Correct handling and storage of drugs and medicines is critical in ensuring that they remain functional and safe to use. Regular monitoring and data capture highlights trends and issues not evident from manual record keeping. Over weekends and during holiday periods readings may not be recorded. Failure of a refrigerator or break in power supply could render contents unusable or remain undetected
 
EveryWare has developed an intelligent software platform with smart sensors, integrated and modular, in conjunction with clinicians to tackle this major problem. Local devices monitor a range of parameters, including ambient temperature, pressure and humidity; together with refrigeration temperatures at different levels within each unit
 
Local and remote alerts can be triggered when your own defined rules are breached. Alerts may be visual and audible in a monitored location with users receiving direct notifications via email, SMS and other channels. Data is visualized and accessible on computers, tablets and smartphones
 
Testimonial
Clinical bodies and Trusts’ guidelines require regular monitoring of critical storage temperatures. Legislation requires that records are kept and this is often a manual task with readings taken at up to 24 hour intervals
 
Successful trials yielded a wealth of information for pharmacy staff to gain immediate, real time insight into how efficient their refrigerators are and how ambient conditions and working practices affect them. Clinicians benefit from the reduced workload and the availability of high resolution data proves compliance with healthcare guidelines 24/7

Differences between types of refrigerator become evident. Recovery time following prolonged periods of access can expose the contents to raised temperatures for longer; trend data clearly demonstrates the effects of daily routines and identifies opportunities for training that will improve the safe storage and dispensing of critical medicines
 
EveryWare’s unique modular system means that the unit cost of the sensors is low. All other costs are capped, so no need to worry about data rates and variable costs. Annual cost of the system is a fraction of the cost of the assets or processes being monitored. System is designed from the ground up to be completely user-configurable to suit local and business requirements. Security is paramount; all cloud systems and data are network-isolated, multiple-passkey protected with encrypted communications.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
Compliant drug storage
There is a legislative requirement to store critical medicines within specified parameters. Moreover, it is imperative that safe storage can be demonstrated and that only safe products are used.
 
Equally, any fault or disruption to the storage infrastructure doesn’t automatically render the products beyond safe use. Smart monitoring, reporting and validation afford peace of mind. Efficacy of the drugs can be evidenced and detect abnormal patterns of behaviour or access issues e.g. refrigerator door left open.
 
Broad clinical guidelines indicate that regular, period monitoring by technicians will suffice; often once every 24 hours and often not during weekends and holiday periods.
 
There are several risks with this approach that can render expensive drugs ineffective and worse still, fail to deliver the anticipated results. A power outage in the early hours or over a weekend may be masked by a reinstatement long before working hours. The damage may already be done if excessive temperatures have been realised.
 
The solution is to introduce smart monitoring with remote data logging and alerts. Continuous, electronic monitoring not only captures specific events 24/7 and raise alarms but provides valuable trend data. Battery backup will buffer mains failure without disruption to the monitoring or connectivity. Real time monitoring has clearly shown systematic issues occur out of working hours and variations within specific refrigerated facilities. Clinical practices will also affect the storage conditions; a feature that is evident from trend data. The effects of prolonged loading and unloading with the refrigerator open shows the impact upon refrigeration temperatures and the extended recovery time to achieve safe storage temperatures when eventually closed. Access to the refrigerators out of prescribed hours may also raise an alert if there is a security concern.
 
EveryWare has installed local monitoring systems in hospitals and clinical environments that are capable of tracking a range of critical conditions. Not just in refrigeration units but ambient conditions in key locations may be monitored through a common network. Within treatment, theatre, storage or living areas the network of wireless devices can track temperature, relative humidity and pressure along with other factors such as controlled access and refrigeration performance.
 
In homes EveryWare could be used with ambient and movement sensors to detect risk of hypothermia or falls.
 
Initial Review Rating
4.60 (2 ratings)
Benefit to WM population:
Overall benefits summary
Installations of the system have already demonstrated potential savings in recent trials.
  • Money saved by GP surgeries and health trusts through proper refrigeration of medicines
  • Money saved by pharmaceuticals companies through proper refrigeration 
  • Money saved by pharmaceuticals companies by not having to pre-emptively over-produce product to compensate for GP and trust wastage
  • Quality of patient care increases as a result of cost savings throughout the medicine supply chain
  • Meets strict legislative requirements ((strict environmental monitoring protocols are now required by CQC. Failure to comply requires drugs be destroyed at very high cost).
  • Modular (easy to add on additional ambient sensors, movements detectors etc)
  • Quick to install and upgrade
  • Predictive analytics software enables custom ‘rules based’ alerts to be created easily
  • Monitor multiple installations and multiple sensors from a single location (Dashboard)
     
Quality control
  • Constant monitoring of refrigeration and the ability to react instantly minimises the amount of wastage caused by medicine being spoiled by high temperatures. The unique modular design enables additional sensors to be quickly integrated. Predictive analytics software enables custom ‘rules based’ alerts and monitoring protocols to be easily created and monitored.
Legislation
  • The easy monitoring of temperatures makes it much easier to comply with the strict legislation imposed by health bodies such as the MHRA and CQC.
     
GP Surgeries
  • Surgeries and trusts are able to monitor the temperature of their drugs in the refrigerator and react instantly should parameters be broken.
     
Patient care
  • The cost savings made by reducing wastage can be channelled back into the healthcare system, improving overall patient care.
For more information see: http://www.everyware.uk.com/products/21st-century-drug-monitoring
Current and planned activity: 
Current Activity
Successful trials have been conducted with SWFT Clinical Services Ltd (a subsidiary of the South Warwickshire NHS Foundation Trust) which yielded a wealth of information for pharmacy staff to gain immediate, real time insight into how efficient their refrigerators are and how ambient conditions and working practices affect them.
 
Positive actions were taken to improve the effectiveness and avoid potential problems that might have occurred. Clinicians benefit from the reduced workload and the availability of high resolution data proves compliance with healthcare guidelines 24/7.
 
We have recently entered discussions with GP practice in Norfolk in response to CQC’s strict environmental monitoring requirement for drug storage.

Planned Activity
  • We would welcome NHS input in our systems design and further development
  • We wish to increase awareness within GP and CCGs
  • We are seeking additional trial sites
What is the intellectual property status of your innovation?:
All IP resides with the company
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Nigel Maris 18/10/2016 - 08:42 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Tipsim® is a completely new product producing long lasting improvements in sensorimotor abilities of the hand in rehabilitation after brain damage, such as stroke, craniocerebral trauma or other neuro diseases e.g. Complex Regional Pain Syndrome.
Overview of Innovation:
Tip-stimulation with Tipstim® facilitates long-lasting therapy procedures. By sensory stimulation of the finger tips, Tipstim® drives plasticity processes in cerebral areas involved in the activation of the hand and fingers. Specially designed stimulation patterns – developed over many years of research & trials at the Institute for Neuroinformatics at the Ruhr University Bochum – are generated by a small, portable electronic pulse generator and applied directly to the finger tips via a completely new and highly-sophisticated therapy glove. The Tipstim glove® is the first product of its kind to utilise a new advanced medically approved conductive and biocompatible textile.
 
The therapy is completely painless, without side-effects and very easy to apply. The patient simply pulls over the glove, connects it to the pulse generator and starts the therapy session once a day for 1 hour. The therapy does not demand any special attention from the patient. Due to the small size of the pulse generator, the therapy can easily be integrated into everyday life and home. In principle, therapy can be applied everywhere, even when out walking.


 The proven efficiency of Tipstim® results from stimulation pattern specially designed for most effective enforcement of neuroplasticity processes. Clinical studies show that these special patterns produce cerebral changes which lead to persistent improvement of a patient’s sensorimotor abilities. This especially true with sensory and proprioceptive deficits which have shown a greater recovery than with standard rehabilitation therapy alone
 
Studies have shown that sensory stimulation drives plastic processes in the brain areas activated by the stimulation. This induces reorganisation in and around those brain areas that became dysfunctional by stroke or other brain injuries. This reorganization facilitates reactivation of cortical tissue that has preserved some functionality. The resulting remodelling of cortical circuits then mediates functional recovery.
 
Tipstim® is a clinically tested and CE approved product. The efficacy & safety of Tipstim® therapy has been proven in rigorous clinical trials.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Person centred care
Benefit to NHS:
Stroke is the UK’s third biggest killer.
 
First-time incidence of stroke occurs almost 17 million times a year worldwide; one every two seconds. Stroke is one of the largest causes of disability – half of all stroke survivors have a disability.
 
In the UK there are 152,000 recorded incidences of stroke a year and currently over 1.2 million stroke survivors. The economic costs of stroke in the UK from a societal perspective totals around £9 billion a year (Source: State of the Nation Stroke statistics - January 2016). The average cost of care (acute & rehabilitation) per stroke patient is currently £23,315 (National Audit Office. Progress in improving stroke care..., (February 2010). NAO Report (HC 291 2009-2010))
 
Over a third of stroke survivors in the UK are dependent on others.
 
Tipstim® is a completely new product to improve sensorimotor abilities of the hand in rehabilitation after brain damage, such as stroke, craniocerebral trauma and other neurological diseases such as Complex Regional Pain Syndrome.
 
Tipstim® comprises a small, battery powered electronic pulse generator unit and a close fitting glove that delivers the neurostimulation at the finger tips. Due to the compact size of the pulse generator, the therapy can easily be integrated into everyday life. In principle, therapy can be delivered everywhere, even during walking or when reading or watching television.
 
Clinical trials have demonstrated that the stimulation provided by Tipstim®  demonstrates a persistant reactivation of affected brain areas responsible to sensory and motor control of the hand and fingers. Moreover, balancing processes in adjacent non-affected brain areas are promoted.
The result is a substantially improved sense of touch as well as an improved mobility of the concerned hand.
 
The sensory & functional improvements resulting from Tipstim® neurostimulation have been demonstrated to last longer than for traditional therapy alone.
 
The Tipstim® is self contained and can easily be used by the patient in their own home. This reduces the frequency of hospital / clinic visits, frees up therapist time and would enable more patients to be treated than is currently possible.
 
Furthermore, the sensory and functional improvements resulting from the Tipstim® therapy will increase the patient’s ability to carry out task of daily living and will therefore increase their independence, thus reducing the need for additional care and support – with resultant manpower and monetary savings.
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
The West Midlands has the highest mortality for stroke in England in people over 65.
 
The region’s ethnic diversity and socioeconomic status also reflects in a higher than average incidence of strokes as people of black and South Asian origin are at double the risk of stroke as are those living in the most economically deprived areas of the UK (West Midlands has 28.1% of its population in the most deprived national quintile)
 
These statistics demonstrate that the demand for stroke rehabilitation services will be higher than the national average and therefore the opportunity to make a significant impact will be greater for therapies such as Tipstim®.
 
The region also has the lowest percentage of patients returning to their usual place of residence, and this is statistically significantly lower than the England average. Improved  independence and post stroke rehabilitation would help to address this and enable people to return to their own homes and live independently.
Current and planned activity: 
We are currently undertaking a pilot multicentre clinical trial of Tipstim® at the Countess of Chester NHS Foundation Trust, Chester.
We would welcome the opportunity to engage with the West Midland’s Stroke rehabilitation communities to raise awareness of our Tipstim®.
In addition, we wish to explore support for business model development and delivery strategies for NHS adoption and or private procurement.

We are also very interested in conducting a cost benefits analysis health economics study of therapeutic intervention with Tipstim®.
What is the intellectual property status of your innovation?:
Tipstim® is protected via granted patents and registered design rights held by the parent company.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:
Please describe how the innovation could be scaled across the WM region. Have you implemented at scale in any other regions?
Measures:
What outcomes are you hoping to achieve and what are the measures that you will use to gauge the success of the innovation and how will these assessments be made? Please ensure that you have quality, safety, cost and people measures.
Adoption target:
What are the targets for adoption across the WM and what are the minimum viability levels?
Read more
Hide details
Bharat Vadukul 21/09/2016 - 12:15 Detailed Submission 1 comment
0
0
Votes
-99999
Innovation 'Elevator Pitch':
The i-THRIVE programme aims to improve children and young people’s mental health outcomes by working with 30 sites across the country to implement the THRIVE framework.
Overview of Innovation:
i-THRIVE is national programme of innovation and improvement in child and adolescent mental health. It is an NHS Innovation Accelerator and is currently being implemented in national accelerator sites across the country. It is delivered by supporting localities to implement the THRIVE Framework through their CAMHS transformation and service improvement programmes.

i-THRIVE Community of Practice 
More than 30 sites make up the i-THRIVE Community of Practice. The Community of Practice includes organisations that are using the THRIVE framework as the basis of their CAMHS transformation and improvement programmes who then share learning about the implementation of THRIVE and how it can be adopted to fit with their local plans for service redesign. Nearly 25% of the young people in England live within a locality that is a member of the i-THRIVE Community of Practice.

THRIVE
THRIVE Elaborated (Wolpert et al, 2015) can be downloaded here: THRIVE Elaborated

i-THRIVE
i-THRIVE is the implementation of the THRIVE conceptual framework, translating the THRIVE core principles into models of care that fit local contexts. Key to this process is the use of evidence based approaches to implementation.
 
i-THRIVE supports the provision of services using a whole-system, or place-based, approach to the delivery of child mental health services. This involves taking a population approach to delivery of care; enabling integration across health, care, education and third sectors, and a central focus on delivering improved outcomes for children and young people.
 
Choice and personalisation of care are core values and these are delivered in part through systematic implementation of shared decision making. To support this, a range of validated measures, tools and educational programmes have been developed by partners and are included in the i-THRIVE Implementation Toolkit, including the CollaboRATE measure, Option Grids and shared decision making training through the i-THRIVE Academy.

i-THRIVE Partnership Organisations
i-THRIVE is delivered through a partnership between the Anna Freud National Centre for Children and Families, the Tavistock and Portman NHS Foundation Trust, the Dartmouth Centre for Healthcare Delivery Science and UCLPartners.

Further Information
Further information about i-THRIVE and examples of successful implementation in sites can be found at http://www.implementingthrive.org/. For the latest news and updates you can also follow us on Twitter: @iTHRIVEinfo.
Stage of Development:
Trial stage - Trial stage to prove that the idea actually works as intended
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Innovation and adoption / Person centred care
Benefit to NHS:
i-THRIVE and the THRIVE framework have been developed to align with and to support established system transformation and quality improvement methodology. The i-THRIVE model is aligned to emerging tariff payments and is identified within Future in Mind as a suggested model of care.
 
i-THRIVE encapsulates many of the key strategic requirements for delivering CAMHS over the next few years. The NHS Five Year Forward View emphasises services being person-centered, the importance of early intervention, taking a whole system approach and enabling self-care, all of which are core to the THRIVE framework and in the delivery of i-THRIVE. By supporting sites to deliver i-THRIVE we will be helping them to deliver the changes called for in Future in Mind.

Expected benefits include increased proportion of young people accessing CAMHS with higher proportional improvement in vulnerable groups due to outreach and the location and accessibility of assessment services. There will be increased use of community services, self-care and peer-support networks as a result of effective signposting. We expect to see a reduction in waiting times and increased engagement with services with young people involved in co-designing services, their care and in peer-support networks. Efficiency gains are also expected.
Initial Review Rating
4.40 (2 ratings)
Benefit to WM population:
We are currently working with sites in the West Midlands to support them in the delivery of i-THRIVE.
Current and planned activity: 
i-THRIVE is currently supporting 30 sites across the country to develop and implement the THRIVE framework as part of their CAMHS transformation plans. The programme is funded by Health Education England, The Health Foundation and the NHS Innovation Accelerator to directly support NHS sites  and their partners in local government, education and the third sector, by providing learning and development resources, sharing evidence based tools for implementation, the sharing of good practice and support for evaluation.
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
3
Read more
Hide details
Emma Louisy 06/09/2016 - 14:24 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Flo-Tone CR is a tool helping patients acquire good Maintenance & Technique in using Pressurised Inhalers, teaching how to Inhale SLOWLY and STEADILY. Inhaler Technique Skills are important and a major theme in BTS, GINA and NICE guidance.
Overview of Innovation:
Flo-Tone MDI (also known as Flo-Tone CR) uses a ‘Positive’ Coaching Whistle to help patients learn to inhale SLOWLY and STEADILY. Whistle Signal is a prompt for the canister to be pressed releasing the medication & the duration of the Whistle helps the professional to coach the patient towards correct use.
Pressurised inhaler mouthpieces come in a variety of shapes, accordingly Flo-Tone was originally produced in ‘Circular’ & ‘Regular’ Models. A new improved Flo-Tone CR now fits all mouthpiece shapes by fitting inside the pMDI mouthpiece. The new design ensures all pMDIs produce a whistle at the same flow rate, helping standardise technique.
Studies have been conducted with the new Flo-Tone to ensure that it delivers the full dose. The first study detailing the development of the improvement & its performance was presented at BTS 2015 & subsequently at DDL26.
Available on prescription, the improved Flo-Tone CR can be used with a pMDI simulator (Trainhaler) for training & with the Patient pMDI. It incorporates a cap so that it can be left in situ on the Inhaler. It also includes a rim on the mouthpiece to help patients get their teeth out of the way of the aerosol spray.
We have tested Flo-Tone CR with a variety of inhaled medications (Flutiform, Clenil, Ventolin, QVAR and Sirdupla) – in each case the respirable dose (ie that part that reaches the lungs) delivered for the medication plus Flo-Tone closely matched that of the device alone & in each case unwanted throat deposition was reduced.
•Flo-Tone CR controls the resistance of the pMDI, thereby standardising the flow rate at which  
  Flo-Tone CR whistles
•Provide inhalation & coordination guidance
•Sounds (20-25 L/min)
•Drug delivery improvement = Therapeutic Improvement
•Less throat deposition – potentially less unwanted Throat Side-Effects
•Better control - less breakthrough – less SABA needed
•Better control – less hospitalisation 


• Spacer & Mask with anti-Microbial & anti-static properties
Collapsible – helps with storage & travel
• Visible valve movement - see that the drug is being Inhaled
• Suitable for adults & children
• Performance validated with pMDI’s
• Accepts all pMDI’s available
• Available with small & medium mask


• Ideal for emergency services use, schools & within General Practice & Hospitals for reversibility testing
• Single patient use
• Economical & environmentally friendly
• Performance validated with pMDI’s
• Available in bulk pack 
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
There have been many papers published, detailing the misuse of pMDI among patients;
Clement Clarke International have used their expertise to concentrate on this area of products. This
has led to the introduction of the ‘Inhaler Technique Training’ range. Each device is targeted at the
training of inhalation technique, guiding patients to inhale at the correct flow rate for pMDI use.
 
Inhaler technique errors occur in the hands of patients and healthcare professionals. It has been
demonstrated that the majority of healthcare professionals cannot demonstrate correct inhaler use
to their patients. It is not therefore surprising that patients are mostly unable to demonstrate good
inhaler technique. The consequences are significant; patients take higher doses to compensate for
lack of efficacy from medication lost through poor technique, this results in poorer control,
hospitalisation and increased healthcare costs.

The Clement Clarke ‘Inhaler Technique Training’ range delivers more reliable, more effective and patient friendly usage of medication and treatment (therapy) delivery.
Benefits summary
  • Patient friendly medication management and use
  • More effective and accurate delivery of medication to lungs
  • Reduced number of hospital admissions
  • Reduced number of un-planned clinical interventions
  • Reduced associated therapeutic costs
  • Improved patients’ health and quality of life
  • Available on the National Drug Tariff
  • Low cost devices
  • Available for immediate use
Initial Review Rating
4.00 (2 ratings)
Benefit to WM population:
The West Midlands region provides a great opportunity for rapid realisation of the benefits of improved inhaler training from a clinical, economic and patients’ quality of life perspectives.

All the required products and training materials are currently available for instant deployment and would offer significant benefits to those GP practices or secondary care providers willing to challenge existing ineffective training and delivery mechanisms and who would act as either the Regional or National adoption lead.
 
A comprehensive breakdown of the tools and devices required for a GP practice has been provided in an attached document (Essential Requirements for GP Practice Inhaler Training Kits).
Current and planned activity: 
Current NHS activity
Key areas of Contact are Lung Function & Respiratory Medicine which include Respiratory Physiologists & Respiratory Nurses both in Adults & Paediatrics.
 
Flo-Tone has been adopted by Wolverhampton CCG.

Planned/required activity
As a Manufacturer, Clement Clarke undertakes an extensive R&D program and also undertakes On-Site Clinical Trials with GP Practice & Secondary Care.
However, research and trials support partners would be welcomed to further develop the evidence base demonstrating the benefits of improved staff training with associated patient benefits.
In addition, Health Economic studies would also be welcomed to quantify the medication and admission cost savings that would be achieved. This would supplement the Isle of Wight study and include a wider geographical and ethnic / demographic patient cohort.
What is the intellectual property status of your innovation?:
All intellectual Property for devices and training is held by Clement Clarke International
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
3
Read more
Hide details
Anthony Silvio Philips 31/08/2016 - 10:46 Publish Login or Register to post comments
4
1
Votes
-99999
Innovation 'Elevator Pitch':
An engaging educational board game and HTML5 web app to help children with Cystic Fibrosis, and their families, to improve their understanding of the condition and how to manage it.
Overview of Innovation:
The game is designed to help children and families manage Cystic Fibrosis more effectively. Originally created by specialists at Coventry & Warwickshire Partnership NHS Trust to help healthcare professionals develop a more effective relationship with young patients and their families. The game was so effective that Focus Games Ltd was asked to redesign and streamline the game and make it available to a wider audience.

The game is designed for between 2 and 4 individual players (or small teams of players) who compete to move around the board answering CF-related questions and scenarios correctly. The game is very easy to play and doesn’t require a specialist facilitator; anyone can play the game. This makes it ideal for use in the home and at school with family, friends and schoolmates.
 
Objectives
To help young patients, their families and friends to improve their understanding of Cystic Fibrosis and to manage the condition more effectively.
 
A patient engagement tool for healthcare specialists to use:
  • Children with Cystic Fibrosis
  • Families & friends of CF patients
  • Schools
  • Public health awareness
Can be used in:
  • CF clinics
  • Other healthcare settings
  • At home
  • In school
The board game is very portable, the rules are very simple and specialist facilitation skills are not required so the game can be played by anybody in any setting.
 
The board game is competitive and accommodates up to 4 individual  players, or teams of players. Games last between 45 and 60 minutes.

The HTML5 web app is a simplified version of the board game designed for individuals to use on smartphones, tablets and desktop PCs. However, it can also be used with groups on tablets, screens and interactive whitebboards etc.
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
The original game was developed by Coventry and Warwickshire Partnership NHS Trust and Focus Games Ltd has refined and reworked the game to make it more engaging and more likley to suceed as a commercial product. This process was supported byMidTECH Innovations (NHS Innovations West Midlands).

Benefits to the NHS include:  
  • Increased  knowledge of CF not just for the patient but for the whole family and improved engagement with the CF Team - This would help give children and young people a sense of control in managing their condition. Symptoms are recognised by CF patients and parents early and acted upon so infections are treated quickly therefore less time would be spent as in an inpatient making savings on bed space and staffing.
  • Increased understanding of treatments - Children can express and explore their fears and emotions in a safe place. Play provides the medium to help manage these feelings and therefore promotes resilience
  • Improved  compliance with treatment – Children and young people with CF will often have multiple treatment regimens to follow. The CF game gives an understanding of why particular treatments/medicines need to be adhered to. Compliance would mean improved and less stressful visits for treatments and hospital appointments where children are having to be persuaded  to comply with cough swabs/lung function tests etc. This can take up a considerable amount of time for nurses and Doctors both in the Community and the Hospital.
Initial Review Rating
3.40 (1 ratings)
Benefit to WM population:
All of the benefits that the game could deliver for the NHS would benefit the WM population. In addition the game has been developed by a WM NHS Trust and as such the publicity and any shared revenue will be focussed on the WM.
Current and planned activity: 
The original game was developed by Coventry and Warwickshire Partnership NHS Trust and Focus Games Ltd has refined and reworked the game to make it more engaging and more likley to suceed as a commercial product. This process was supported byMidTECH Innovations (NHS Innovations West Midlands).

The board game has been tested within the NHS and also by members of patient support groups. Feedback has been positive and we now wish to extend the scope of testing to cover a more sophisticated online version of the game and also to manufacture the board game.
What is the intellectual property status of your innovation?:
The IP is owned by Coventry and Warwickshire Partnership NHS Trust, and used by Focus Games Ltd under licence from them.
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
2
Regional Scalability:
This game is designed to be used anywhere in the UK, and possibly overseas. We have not yet secured the funding to launch the game commercially. However, we have launched many other games that are being used extensively in the UK and overseas so we are confident that the model works.
Measures:
The most practical measure will be the collection of qualitative feedback from users both patients, carers and healthcare professionals. This would include ongoing questions about any changes to lifestyle and treatement adeherence. This being done for many other existing games that we have published. We would also approach independent stakeholders and hope to encourage them to study the efficacy of the game.
Read more
Hide details
Andy Yeoman 24/08/2016 - 15:08 Sign Posted Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
Disruptive technology prevents Left Ventricular remodelling post MI & promotes tissue regeneration. Product result of £10M EU investment & 5 years R&D. Biocompatible & Biodegradable product demonstrated pre-clinically in wide range of animal model.
Overview of Innovation:
Cardiac patch is a scaffold structure compatible with in-vitro cell seeding & cell culture used as a vector for cellular therapy in addition to structural support. Numerous applications include curettage & cardiac transmural use in addition to soft tissue engineering such as hernias & vein repair. Scaffold composition comprises poly(caprolactone), alginate & composites thereof with natural polymers such as chitosan & alginate fibroin decorated with a synthetic peptidic hydrogel. Porosity can be tailored with pore range of 10-250µm, permitting angiogenesis and cell seeding. Although the biomaterial can be used independently as a medical device for prosthetic applications, its main tissue engineering function is to enhance cell attachment, growth & differentiation. An extension of the device is its functionalisation with cell signalling agent capacity providing the scaffold with extracellular matrix like micro-environment. Polymeric self-assembled structure is composed of but not limited to peptidic or polyurethane amphiphiles & can be loaded with chemical & biological cues covalently or via entrapment.

To initiate regeneration, the biomaterial must encourage in-vivo revascularisation & promote integration with host tissue. Concurrently, it should biodegrade at the same rate that newly formed tissue replaces it, being removed from the body by natural metabolic pathways without toxic by-products.

The patch provides both a temporary mechanical support to the infarcted myocardium preventing further damage to the surrounding tissue and prevents aneurism formation in the infarcted area whilst regeneration take place

Myocardial infarct treatment
Device can be used for in-vitro & in-vivo applications. Both parts of the device can be loaded with cell signalling agents or drugs for research & clinical use. Fibre based secondary drug delivery structure allows multiple growth factor/drug release with different release profiles as a direct tool for gel functionalisation with patient blood components in-vivo.

The system’s mechanical properties match the tissue it replaces. 3D hydrophobic/hydrophilic scaffold provides mechanical support to a gel that acts as scaffold plasticizer & provides an hydrophilic interface with host environment. The gel can also collect cell signalling agents from its immediate environment. The electrospun fibre based drug delivery system can additionally be used as a complementary tool to the gel for loading with cell signalling agents, drugs etc
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Innovation and adoption / Person centred care
Benefit to NHS:
The leading global trend in interventional cardiology is to adopt less invasive technologies, reducing patient recovery time & improving quality of life.
 
PeptiGelDesign Cardiac Patch treats myocardial infarction (MI). Current treatments are based on medication &/or organ transplantation. Approx. 4,600 heart transplants are carried out pa in Europe & the USA (1,900 EU). Even with current medical management, over 1/3 of acute heart attacks are fatal. Rehabilitation levels following MI are variable with major damage unable to be fully healed. Current treatments to prevent tissue damage post MI include thrombolytic agents. These drugs have greatly reduced morbidity & mortality, but must be administered within a short interval following MI to be effective. Cardiac catheterization & Angioplasty have proven effective in restoring blood flow, but cannot reverse tissue damage. Transplantation is complicated surgery, severely limited by lack of donor organs.


Advantages of cardiac patch over current treatment regimes:
 
• Complements established therapies restoring damaged cardiac muscle ensuring improved contractility function & eliminating CHD related early mortality. Following non-lethal MI current treatments effectively restore blood flow, but cannot reverse tissue damage leading to limited rehabilitation & QoL
 
• Restoration of cardiac function drastically reduces re-infarction rates & need for subsequent interventions.


• Demonstrably increases life expectancy post MI. In cases of CABG (bypass), 5-year mortality rate for target population (patients with abnormal Left Ventricular (LV) function typically caused by MI) is 16.5% vs a mortality rate for patients with normal LV function of 8.5% (50% improvement). We could expect the cardiac patch to reduce mortality of patients undergoing MI to the level of those with normal LV function due to recovery of infarcted heart. Similarly, 5-year mortality rate of 80% for post MI patients undergoing an interventional procedure decreases to 40% - the mortality rate for patients undergoing the same procedure but with normal LV function.


• By enabling recovery of the heart muscle patients improve their NYHA class, suffer less Angina Pectoris, reduced incidence  of re-infarction, need less medication & hospitalization & improve QoL. NB: 10 years post CABG intervention, overall survival rate is 69% vs overall event free rate of 41%, suggesting that a significant portion of patients are surviving but with a fairly low QoL
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
In addition to the many benefits to the wider NHS outlined above, there are specific regional benefits accruing from the adoption of this medical device and treatment regime.
 
The high incidence of Chronic Heart Disease and the costly rehabilitation of patients post heart attack is a recognised priority within the West Midlands population.
 
The cardiac patch offers a minimally invasive and rapidly deployable intervention that will significantly improve the quality of life for patients surviving Myocardial Infarction.
 
In addition, the cost and time savings to the NHS and social care through improving patient outcomes, reduced number of transplants and greater quality of life and increased independence for patients post MI will be significant.
Current and planned activity: 
(See attached document for more information)
PeptiGelDesign is currently engaged with the Liverpool Heart and Chest Hospital.

Wish to partner with NHS and NHS Research Organisations on clinical trials for cardiac patch development.

As our primary target market is the UK, we wish to raise profile within the NHS and work with its stakeholders to bring our technology to the market and ultimately to the patient.
  • Explore if entitled to an  Investigational Device Exemption (IDE) ?
  • Identify sources of funding to support PeptiGelDesign pursuing the further validation.
  • Procurement/Adoption: -  Require routes to GP sales - marketing products to CCGs
  • Evaluation/Validation/Clinical Trial - Need to gain additional validation - seeking a trial centre.
  • Concept Development - This is planned development work but seeking NHS partnership/advice.
Project Assistance required - The Company is interested in locating clinical/academic collaborators for new product development.
What is the intellectual property status of your innovation?:
PeptiGelDesign Ltd is licencing the WO2014044321 and finance patent granting process. Today, the patent has been accepted in USA, EU and Japan and will enter EU countries national phase in December 2016.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Read more
Hide details
Guillaume Saint-Pierre 04/08/2016 - 08:33 Publish 1 comment
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Half a million adults and children in the UK experience severe asthma symptoms despite high dose medication. Air4 offers a non pharmacological treatment of allergic disease using Temperature Laminar Airflow to reduce exposure to allergens in the bed.
Overview of Innovation:
Air4 is a unique, innovative medical device which uses Temperture Laminar Airflow (TLA) technology to protect patients with severe allergic asthma and eczema, from exposure to allergens and other airborne particles (pollens, housedust mite and animal danders etc.) that are in and around the bed at night whilst they sleep. The device has no side effects and can therefore be used for adults and children.

Air4 is installed in the bedroom alongside the bed; air is drawn in the device from the room where it is filtered and cooled to 0.5-0.8 degrees centigrade lower than the ambient temperature. As cool air is heavier than room temperature, gravity ensures the air gradually descends without an excessive breeze or draught creating the patients breathing zone; due to the density of the air in the breathing zone airborne allergens are unable to penetrate and therefore the patient sleeps in an allergen free zone.

In reducing the airborne allergens the device has shown in clinical trials that is has reduced exacerbations and the number of hosptial admissions; it has reduced day and night time symptoms in patients and improved quality of life (health related) and has shown to reduce the number of days off work/school.

Air4 has a Medical Technology Innovation briefing from NICE stating the device is clinically and cost effective.There is also an Innovation Medical Technology Overview  from Helath Improve Scotland showing the device is clinically and cost effective compared to standard treatment.

Using the Air4 in adults or children who are still symptomatic despite maximum inhaler treatment; can avoid long term side effects from oral corticosteroids as well as the regular hospital visits from other treatmenst

 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Innovation and adoption / Person centred care
Benefit to NHS:
  • Reduction in exacerbations leading to fewer hospital admissions and clinic visits
  • Reduction in use of rescue medication leading to a reduction in drug spend
  • Reduction in the number of days taken off school and work
  • Cost effective and in some circumstances cost saving treatment. Annual rental cost is offset by the economc savings in medical costs resulting in a net cost to the NHS 
  • Fulfils Care closer to home: encouraging people to live independently; provide greater choice and control over health; Reduce NHS costs and the demands for hospital resources
Initial Review Rating
4.20 (2 ratings)
Benefit to WM population:
Home based overnight treatment which negates the need for hospital stays.
Improvement in quality of life (HRQLS)
Improvement in sleep
Reduction in the need for rescue medication
Reduction in exacerbations and therefore hospital stays and clinic visits.
Current and planned activity: 
Current Activity: Ongoing UK trial (LASER) with results due in spring 2017 (West Midlands have 2 investigator sites)
                          Working with Innovation Nexus Greater Manchester to support clinicians use of Air4
 Current Device Use: Royal Wolverhampton, Hereford
Planned Device Use: Birmingham Childrens, Sandwell, Worcester
What is the intellectual property status of your innovation?:
IP is held by the company
Current Certification: Class 1 Medical Device; CE Marked
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
Air4 is already being used in several accounts across the West Midlands with several more interested in trying the device. From a company perspective the warehouse will be informed of potential numbers and they will increase production to ensure they can meet with the increase in demand
Measures:
Overall measure of success of our innovation will be to see it accepted as a standard of care treatement for allergic disease and no longer applied for by an IFR for clinical exceptionality.
Quality Measures: Airsonett has implemented a quality management system compliant with ISO 9001, 13485 and QSR
Safety: Air4 is a CE marked class 1 medical device. As it is a non pharmacological device there are no known side effects and the device is installed,set up and removed by trained technicians.
Cost: There has been an economic analysis published in the BMJ Open Respiratory Research which found that the Air4 was a cost effective addition to standard treatment in patients with severe uncontrolled atopic asthma. These high risk patients with severe atopic asthma who use Air4 could reduce the incidence of hospitalization which could be cost saving to the NHS. Brazier et al (2015)         Airsonett® would be added to existing treatment and the average cost of long term treatment is £5.72 per day. Estimated cost of add on therapy currently used in the NHS is Omalizumab at approximately £23 per day.
The cost utility analysis estimated an incremental cost effectiveness ratio (ICER) of £8998 per quality of life adjusted year (QALY) with Airsonett®® compared to NHS standard care based on an incremental cost of £553 and a QALY gain of 0.0615. http://www.nice.org.uk/advice/MIB8/chapter/Technology-overview
People Measures:Success of the device will be measured using the following key performance indicators at 3 months for children and 6 months for adults: Improvement in the Asthma Control Test (ACT); reduction in exacerbations (compared to previous 12 months); reduction in or stopping of oral corticosteroids; Improvement in the Asthma Quality of Life Scores, adult and children (AQLQ: PAQLQ) and also improvement in sleep, work/school, and comorbid allergic disease such as eczema and/or perinnial rhinitis.
Adoption target:
Currently in WM there are 2 sites in the Laser trial (adult) and 2 sites (Paediatrics) who have patients on the device; approximately 5 additional sites across the WM with an interest. Based on the current interested sites I would estimate in the first year approximately 30 patients.
Read more
Hide details
Sarah Renshaw 03/08/2016 - 13:59 Detailed Submission 1 comment
0
0
Votes
-99999
Innovation 'Elevator Pitch':
A comprehensive package of training and development on safegaurding adults, mental capacity, deprivation of liberty safeguards and Prevent delivered through training DVDs, e-learning packages, patient stories, face-to-face training and webinars. 
Overview of Innovation:
Safeguarding Adults, Mental Capacity and Deprivation of Liberty Safeguards are mandatory training for all staff working with vulnerable adults across the health and social care economy. As this inevitably requires large numbers of staff, organisations are constantly being challenged with meeting the training compliance needed. This training is also required every 3 years.

This flexible training package is designed to meet the training needs of various organisations who have statutory obligations in this area. The training package includes:

- Safeguarding adults level 1 raising awareness 
- Safeguarding adults level 2 alerter/referrer 
- Safeguarding adults level 3 section 42 enquiries/case conference 
- Mental Capacity Act introduction
- Mental Capacity Act in practice
- Deprivation of Liberty introduction
- Deprivation of Liberty in practice
- Prevent
- Specialist modules on
    * self-neglect
    * modern day slavery and human trafficking
    * Female genital mutilation (FGM)
    * Domestic violence

These training modules can be delivered via:

- E-learning package including anonymised real patient story videos developed by the Trust
- Face-to-face for more advanced training
- Webinars
- Bespoke training individually costed
- Educational material such as booklets, posters, leaflets

All educational and training material can be customised to include the receiving organisation's branding and logo.

More bespoke services include:
- Organisational Review of existing safeguarding processes ,policies and procedures
- Develop safeguarding plan based on gap analysis
- Policy Development
- Risk Assessment, Care planning, report writing , Court reports
- Individual management reviews for SAR’s Domestic Homicide reviews
- Audit Evaluation and Implementation Plan
- Organisational preparation for CQC Inspections
- Organisational quality, risk and governance assurance
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
- Flexible learning packages to meet mandatory training requirements for NHS organisations who do not have the capacity to provide the training in-house
- Improving the knowledge and skills of the workforce which will improve the safeguarding of patients
- Reduce organisational risk
- Improve outcomes for patients and carers
- Reduces demands on clinical time by way of providing training through e-learning
- Access to the most up-to-date contents as our team are constantly updating the training material
Online Discussion Rating
4.00 (1 ratings)
Initial Review Rating
3.80 (2 ratings)
Benefit to WM population:
The safeguarding of vulnerable adults is now statutory under the Care Act 2014. As such, its implementation is required locally, regionally and nationally.

According to the editorial of Journal of Adult Protection Vol 18, No 2, 2016: "Across West Midlands, local authorities are struggling with the effects of austerity measures, unprotected social care budgets, restructuring, under-valued care workers, redundancies and more generally on the rising demands associated with an ageing society". Following re-organisation, many of the local authorities are struggling with a younger and less-experienced workforce with less intellectual memory and too many agency staff. This will be even more so in West Midlands following the councils' devolution plan delivery. This calls for increased training and support for staff delivering front-line services where demands have risen and resourses have dwindled. 
Current and planned activity: 
Currently we provide training to BCHCFT workforce which comprises over 5,000 members of staff. In addition, we provide training to limited number of NHS Trusts and a wider workforce in hospice care, special schools and some private and commissioning groups. All of this has been achieved through recommendations rather than utilising any marketing strategies.
What is the intellectual property status of your innovation?:
Training material need to be protected.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Regional Scalability:
The service can be provided across the West Midlands Health Authority region.
Measures:
- Provides the organisation across the health and social care with the mandatory training for staff dealing with vulnerable adults
- Knowledge assessment at the end of the training to ascertain the competences acquired by the individuals
Adoption target:
Health and social care organisations and private sector
Read more
Hide details
anne mcgarry 12/07/2016 - 14:18 Sign Posted Login or Register to post comments
0
0
Votes

Recent Activities

Who's In Charge? has been moved from Initial Submission to Publish 3 days 10 hours ago
Lucy Chatwin voted on ScanNav® for Obstetrics Limited First Release (LFR) 7 weeks 3 days ago
Endoscope-i: Endoscopic mobile imaging has been moved from Initial Submission to Publish 9 weeks 2 days ago
Airglove: air warming system for venous access has been moved from Initial Submission to Publish 9 weeks 2 days ago
ScanNav® for Obstetrics Limited First Release (LFR) has been moved from Initial Submission to Publish 11 weeks 3 days ago

Active Campaigns